[
  {
    "brand_name": "Fasenra",
    "inn": "benralizumab",
    "therapy_area": "Respiratory disease",
    "indication": "Asthma",
    "indicated_population": "Asthma (severe, eosinophilic, maintenance, inhaled corticosteroid + long-acting β2-agonist IR, 12 years and older)",
    "label": "Fasenra is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype",
    "hcpcs_code": "J0517",
    "exclusion_criteria": "Concurrent use with another monoclonal antibody therapy.",
    "age_restrictions": "Asthma: 6 years of age and older, EGPA: 18 years and older",
    "prescriber_restrictions": "Asthma: Prescribed by or in consultation with an allergist, immunologist, or pulmonologist. EGPA: Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or rheumatologist",
    "other_criteria": "INITIAL THERAPY: ASTHMA (all of A, B, and C): A) blood eosinophil greater than or equal to 150 cells per microliter within previous 6 weeks or within 6 weeks prior to Fasenra or another monoclonal antibody, B) used an inhaled corticosteroid (ICS) in combination with at least one additional asthma controller/maintenance medication, and C) uncontrolled asthma prior to any asthma monoclonal antibody as defined by one of the following (a, b, c, d, or e):\na) one or more exacerbations requiring a systemic CS in the past year, b) one or more exacerbations requiring hospital/urgent care/emergency department visit in the past year, c) FEV1 less than 80 percent predicted or less than 90 percent predicted for patients less than 18, d) FEV1/FVC less than 0.80, or e) worsened asthma with systemic CS taper. EGPA: (all of A, B, and C): A) active disease, and\nB) currently on systemic CS for at least 4 weeks, and C) blood eosinophil greater than or equal to 150 cells per microliter within previous 4 weeks or prior to treatment with any monoclonal antibody that may alter eosinophil levels.\nCONTINUATION THERAPY: ASTHMA (A and B): A) patient has responded to therapy (e.g., decrease in any of the following: asthma exacerbations, asthma symptoms, hospitalizations, emergency department/urgent care visits, physician visits, requirement for oral corticosteroid therapy) and B) continues to receive therapy with an ICS. EGPA: patient has responded to therapy (e.g. reduced rate of relapse, CS dose reduction, reduced eosinophil levels).",
    "insurer": "Centene"
  },
  {
    "brand_name": "Fasenra",
    "inn": "benralizumab",
    "therapy_area": "Respiratory disease",
    "indication": "Asthma",
    "indicated_population": "Asthma (severe, eosinophilic, add-on maintenance Tx, 6 years and older)",
    "label": "Fasenra is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for the add-on maintenance treatment of patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype",
    "hcpcs_code": "J0517",
    "exclusion_criteria": "Concurrent use with another monoclonal antibody therapy.",
    "age_restrictions": "Asthma: 6 years of age and older, EGPA: 18 years and older",
    "prescriber_restrictions": "Asthma: Prescribed by or in consultation with an allergist, immunologist, or pulmonologist. EGPA: Prescribed by or in consultation with an allergist, immunologist, pulmonologist, or rheumatologist",
    "other_criteria": "INITIAL THERAPY: ASTHMA (all of A, B, and C): A) blood eosinophil greater than or equal to 150 cells per microliter within previous 6 weeks or within 6 weeks prior to Fasenra or another monoclonal antibody, B) used an inhaled corticosteroid (ICS) in combination with at least one additional asthma controller/maintenance medication, and C) uncontrolled asthma prior to any asthma monoclonal antibody as defined by one of the following (a, b, c, d, or e):\na) one or more exacerbations requiring a systemic CS in the past year, b) one or more exacerbations requiring hospital/urgent care/emergency department visit in the past year, c) FEV1 less than 80 percent predicted or less than 90 percent predicted for patients less than 18, d) FEV1/FVC less than 0.80, or e) worsened asthma with systemic CS taper. EGPA: (all of A, B, and C): A) active disease, and\nB) currently on systemic CS for at least 4 weeks, and C) blood eosinophil greater than or equal to 150 cells per microliter within previous 4 weeks or prior to treatment with any monoclonal antibody that may alter eosinophil levels.\nCONTINUATION THERAPY: ASTHMA (A and B): A) patient has responded to therapy (e.g., decrease in any of the following: asthma exacerbations, asthma symptoms, hospitalizations, emergency department/urgent care visits, physician visits, requirement for oral corticosteroid therapy) and B) continues to receive therapy with an ICS. EGPA: patient has responded to therapy (e.g. reduced rate of relapse, CS dose reduction, reduced eosinophil levels).",
    "insurer": "Centene"
  },
  {
    "brand_name": "Haegarda",
    "inn": "human C1 esterase inhibitor",
    "therapy_area": "Genetic disorders",
    "indication": "Hereditary angioedema",
    "indicated_population": "HAE (prophylaxis, 12 years and older)",
    "label": "Haegarda is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older.",
    "hcpcs_code": "J0599",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "prescribed by or in consultation with an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders",
    "other_criteria": "Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II], Prophylaxis, Initial Therapy: approve if the patient has HAE type I or type II confirmed by low levels of functional C1-INH protein (less than 50 percent of normal) at baseline and lower than normal serum C4 levels at baseline. Patient is currently taking Haegarda for prophylaxis - approve if the patient meets the following criteria (i and ii): i) patient has a diagnosis of HAE type I or II, and ii) according to the prescriber, the patient has had a favorable clinical response since initiating Haegarda as prophylactic therapy compared with baseline. For patients with HAE with normal C1 inhibitor, EITHER 1) Patient tested positive for an F12, angiopoietin-1, plasminogen, kininogen-1 (KNG1), heparan sulfateglucosamine 3-O-sulfotransferase 6 (HS3ST6), or myoferlin (MYOF) gene mutation OR 2) Patient has a family history of angioedema and the angioedema was refractory to a trial of high-dose antihistamine therapy for at least one month.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Haegarda",
    "inn": "human C1 esterase inhibitor",
    "therapy_area": "Genetic disorders",
    "indication": "Hereditary angioedema",
    "indicated_population": "HAE (prophylaxis, 6 years and older)",
    "label": "Haegarda is a plasma-derived concentrate of C1 Esterase Inhibitor (Human) (C1-INH) indicated for routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in patients 6 years of age and older.",
    "hcpcs_code": "J0599",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "prescribed by or in consultation with an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders",
    "other_criteria": "Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency [Type I or Type II], Prophylaxis, Initial Therapy: approve if the patient has HAE type I or type II confirmed by low levels of functional C1-INH protein (less than 50 percent of normal) at baseline and lower than normal serum C4 levels at baseline. Patient is currently taking Haegarda for prophylaxis - approve if the patient meets the following criteria (i and ii): i) patient has a diagnosis of HAE type I or II, and ii) according to the prescriber, the patient has had a favorable clinical response since initiating Haegarda as prophylactic therapy compared with baseline. For patients with HAE with normal C1 inhibitor, EITHER 1) Patient tested positive for an F12, angiopoietin-1, plasminogen, kininogen-1 (KNG1), heparan sulfateglucosamine 3-O-sulfotransferase 6 (HS3ST6), or myoferlin (MYOF) gene mutation OR 2) Patient has a family history of angioedema and the angioedema was refractory to a trial of high-dose antihistamine therapy for at least one month.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Increlex",
    "inn": "mecasermin",
    "therapy_area": "Endocrinology",
    "indication": "Growth hormone deficiency",
    "indicated_population": "Growth failure (in pediatrics of 2 to 18 years old, with primary IGFD)",
    "label": "Increlex (mecasermin) injection is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary IGF1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.",
    "hcpcs_code": "J2170",
    "exclusion_criteria": "Pediatric patients with closed epiphyses",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Not available",
    "other_criteria": "Not available",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Solid tumors",
    "indicated_population": "Solid tumors (MSI-H or mismatch repair deficient, met, 2nd line)",
    "label": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Solid tumors",
    "indicated_population": "Solid tumors (TMB-H+, more than 10 mutations per megabase, met, 2nd line)",
    "label": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Cutaneous squamous cell carcinoma",
    "indicated_population": "cSCC (surgery or radiation IR)",
    "label": "Cutaneous Squamous Cell Carcinoma (cSCC)\n• for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Breast cancer",
    "indicated_population": "TNBC (PD-L1+, CPS more than 10, met)",
    "label": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Breast cancer",
    "indicated_population": "TNBC (high risk, early stage, in combi with CT as neoadjuvant, mono as adjuvant after surgery)",
    "label": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Melanoma",
    "indicated_population": "Melanoma (met, ipilimumab IR)",
    "label": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Melanoma",
    "indicated_population": "Melanoma (BRAF V600+, met, BRAF inhibitor IR)",
    "label": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Melanoma",
    "indicated_population": "Melanoma (adjuvant, following complete resection)",
    "label": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Melanoma",
    "indicated_population": "Melanoma (in patients of 12 years and older, with Stage IIB, IIC, or III melanoma following complete resection)",
    "label": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (met, PD-L1 more than 1% TPS, CT IR)",
    "label": "Keytruda  is a programmed death receptor-1 (PD-1)-blocking antibody indicated for Non-Small Cell Lung Cancer (NSCLC):\n• in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.\n• in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.\n• as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:\no Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or\no metastatic.\n• as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease\nprogression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda.\n• for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.\n• as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (met, PD-L1 more than 50% TPS, no EGFR or ALK mutations, naïve)",
    "label": "Keytruda  is a programmed death receptor-1 (PD-1)-blocking antibody indicated for Non-Small Cell Lung Cancer (NSCLC):\n• in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.\n• in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.\n• as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:\no Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or\no metastatic.\n• as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease\nprogression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda.\n• for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.\n• as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (met, squamous, naïve, in combi with carboplatin and either paclitaxel or nab-paclitaxel)",
    "label": "Keytruda  is a programmed death receptor-1 (PD-1)-blocking antibody indicated for Non-Small Cell Lung Cancer (NSCLC):\n• in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.\n• in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.\n• as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:\no Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or\no metastatic.\n• as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease\nprogression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda.\n• for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.\n• as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (stage IB, II, or IIIA, adjuvant, following resection and CT)",
    "label": "Keytruda  is a programmed death receptor-1 (PD-1)-blocking antibody indicated for Non-Small Cell Lung Cancer (NSCLC):\n• in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.\n• in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.\n• as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:\no Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or\no metastatic.\n• as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease\nprogression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda.\n• for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.\n• as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (resectable, combi with CT as neoadjuvant Tx, mono as adjuvant Tx post-surgery)",
    "label": "Keytruda  is a programmed death receptor-1 (PD-1)-blocking antibody indicated for Non-Small Cell Lung Cancer (NSCLC):\n• in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.\n• in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.\n• as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:\no Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or\no metastatic.\n• as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease\nprogression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda.\n• for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.\n• as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (stage III, TPS ≥1%, met, 1L, not candidates for surgical resection or definitive chemoradiation, no EGFR or ALK mutations)",
    "label": "Keytruda  is a programmed death receptor-1 (PD-1)-blocking antibody indicated for Non-Small Cell Lung Cancer (NSCLC):\n• in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.\n• in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.\n• as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:\no Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or\no metastatic.\n• as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease\nprogression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda.\n• for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.\n• as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Non-small cell lung carcinoma",
    "indicated_population": "NSCLC (met, non-squamous, no EGFR or ALK + mutations, naïve, combi with pemetrexed and pt CT)",
    "label": "Keytruda  is a programmed death receptor-1 (PD-1)-blocking antibody indicated for Non-Small Cell Lung Cancer (NSCLC):\n• in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.\n• in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC.\n• as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is:\no Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or\no metastatic.\n• as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease\nprogression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Keytruda.\n• for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.\n• as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Hodgkin lymphoma",
    "indicated_population": "cHL (relapsed, ASCT and brentuximab vedotin IR or IT)",
    "label": "Classical Hodgkin Lymphoma (cHL)\n• for the treatment of adult patients with relapsed or refractory cHL.\n• for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Hodgkin lymphoma",
    "indicated_population": "cHL (relapsed, in paediatrics of age 3 years and older, ASCT IR)",
    "label": "Classical Hodgkin Lymphoma (cHL)\n• for the treatment of adult patients with relapsed or refractory cHL.\n• for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Urothelial carcinoma",
    "indicated_population": "Urothelial carcinoma (met, CT IR)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.\n• as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:\no are not eligible for any platinum-containing chemotherapy, or\no who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy.\n• as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Urothelial carcinoma",
    "indicated_population": "Urothelial carcinoma (CT IT)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.\n• as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:\no are not eligible for any platinum-containing chemotherapy, or\no who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy.\n• as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Urothelial carcinoma",
    "indicated_population": "Urothelial carcinoma ((BCG)-unresponsive, NMIBC, with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.\n• as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:\no are not eligible for any platinum-containing chemotherapy, or\no who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy.\n• as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Urothelial carcinoma",
    "indicated_population": "Urothelial carcinoma (PD-L1+, CPS more than 10, met, cisplatin-containing CT IT)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.\n• as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:\no are not eligible for any platinum-containing chemotherapy, or\no who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy.\n• as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Urothelial carcinoma",
    "indicated_population": "Urothelial carcinoma (met, combi with enfortumab vedotin, CT IT)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.\n• as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:\no are not eligible for any platinum-containing chemotherapy, or\no who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy.\n• as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Urothelial carcinoma",
    "indicated_population": "Urothelial carcinoma (met, combi with enfortumab vedotin)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer.\n• as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:\no are not eligible for any platinum-containing chemotherapy, or\no who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy.\n• as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Gastric cancer",
    "indicated_population": "Gastric or gastroesophageal junction adenocarcinoma (PD-L1+, CPS more than 1, met, CT IR)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.\n• in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA approved test.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Gastric cancer",
    "indicated_population": "Gastric cancer (GEJ adenocarcinoma, PD-L1 with a CPS ≥ 1, HER2+, met, 1L, combi with trastuzumab and CT)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.\n• in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA approved test.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Gastric cancer",
    "indicated_population": "Gastric cancer (HER2-, unresectable or met, 1L, combi with CT)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.\n• in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥ 1) as determined by an FDA approved test.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Head and neck cancer",
    "indicated_population": "HNSCC (PD-L1 more than 50% TPS, CT IR)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.\n• in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.\n• as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.\n• as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Head and neck cancer",
    "indicated_population": "HNSCC (PD-L1 with a CPS more than 1, met, naïve)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.\n• in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.\n• as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.\n• as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Head and neck cancer",
    "indicated_population": "HNSCC (met, naïve, in combi)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.\n• in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.\n• as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.\n• as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Head and neck cancer",
    "indicated_population": "HNSCC (locally advanced, PD-L1 CPS ≥1, neoadjuvant Tx, adjuvant Tx with RT with or without cisplatin, then as single agent)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated:\n• for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.\n• in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC.\n• as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.\n• as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Renal cell carcinoma",
    "indicated_population": "RCC (advanced, in combi with lenvatinib, naïve)",
    "label": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC.\nIt is also indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of\nmetastatic lesions.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Renal cell carcinoma",
    "indicated_population": "RCC (adjuvant, high risk of recurrence following nephrectomy, or following nephrectomy and resection of met lesions)",
    "label": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC.\nIt is also indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of\nmetastatic lesions.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Renal cell carcinoma",
    "indicated_population": "RCC (advanced, 1L, combi with axitinib)",
    "label": "KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC.\nIt is also indicated for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of\nmetastatic lesions.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Hepatocellular carcinoma",
    "indicated_population": "HCC (sorafenib IR)",
    "label": "Keytruda is indicated for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Hepatocellular carcinoma",
    "indicated_population": "HCC (sec to HBV, post systemic Tx)",
    "label": "Keytruda is indicated for the treatment of patients with hepatocellular carcinoma (HCC) secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Merkel cell carcinoma",
    "indicated_population": "MCC (met, recurrent)",
    "label": "Merkel Cell Carcinoma (MCC)\n• for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Cervical cancer",
    "indicated_population": "Cervical cancer (PD-L1+, CPS more than 1, met, CT IR)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated: \n• in combination with chemoradiotherapy, for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer. \n• in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.\n• as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Cervical cancer",
    "indicated_population": "Cervical cancer (met, in combi with CT, with or without bevacizumab, PD-L1+, CPS more than 1)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated: \n• in combination with chemoradiotherapy, for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer. \n• in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.\n• as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Cervical cancer",
    "indicated_population": "Cervical cancer (FIGO stage III-IVA, combi with CRT)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated: \n• in combination with chemoradiotherapy, for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer. \n• in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.\n• as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Colorectal cancer",
    "indicated_population": "mCRC (MSI-H or mismatch repair deficient, met, CT IR)",
    "label": "Keytruda is indicated for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).\nKeytruda is indicated for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Colorectal cancer",
    "indicated_population": "mCRC (MSI-H or mismatch repair deficient, met, naïve)",
    "label": "Keytruda is indicated for the first-line treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC).\nKeytruda is indicated for the treatment of adult and pediatric patients with unresectable or metastatic, microsatellite instability-high (MSI-H) or mismatch repair deficient colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Primary mediastinal B-cell lymphoma",
    "indicated_population": "PMBCL (3rd line)",
    "label": "Primary Mediastinal Large B-Cell Lymphoma (PMBCL)\n• for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Endometrial carcinoma",
    "indicated_population": "Endometrial carcinoma (advanced, dMMR or MSI-H, mono, CT IR, surgery or radiation IT)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated: \n• in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.\n• in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) as determined by an FDAapproved test or not MSI-H, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.\n• as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Endometrial carcinoma",
    "indicated_population": "Endometrial carcinoma (advanced or recurrent, in combi with lenvatinib, CT IR, surgery or radiation IT)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated: \n• in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.\n• in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) as determined by an FDAapproved test or not MSI-H, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.\n• as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Endometrial carcinoma",
    "indicated_population": "Endometrial carcinoma (advanced or recurrent, combi with carboplatin + paclitaxel)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated: \n• in combination with carboplatin and paclitaxel, followed by Keytruda as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma.\n• in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) as determined by an FDAapproved test or not MSI-H, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.\n• as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Esophageal cancer",
    "indicated_population": "Esophageal cancer (PD-L1+, CPS more than 10, met, systemic therapy IR)",
    "label": "Keytruda is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:\n• in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1), or\n• as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA approved test",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Esophageal cancer",
    "indicated_population": "Esophageal cancer (in combi with CT)",
    "label": "Keytruda is indicated for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either:\n• in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with tumors that express PD-L1 (CPS ≥ 1), or\n• as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA approved test",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Biliary cancer",
    "indicated_population": "Biliary cancer (met, combi with gemcitabine + cisplatin)",
    "label": "Keytruda is a programmed death receptor-1 (PD-1)-blocking antibody indicated in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Keytruda",
    "inn": "pembrolizumab",
    "therapy_area": "Oncology",
    "indication": "Mesothelioma",
    "indicated_population": "Mesothelioma (malignant pleural, met, 1L, combi with pemetrexed and platinum CT)",
    "label": "Keytruda is indicated for the malignant pleural mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM.",
    "hcpcs_code": "J9271",
    "exclusion_criteria": "Not available",
    "age_restrictions": "18 and older (except Merkel cell, MSI-H/dMMR tumors, large B-cell lymph, TMB-H, glioma) Glioma - less than 18 years old",
    "prescriber_restrictions": "Prescribed by or in consultation with an oncologist.",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Nivestym/Nivestim",
    "inn": "filgrastim",
    "therapy_area": "Blood disorders",
    "indication": "Neutropenia",
    "indicated_population": "Neutropenia (febrile, severe, nonmyeloid malignancies)",
    "label": "NIVESTYM is a leukocyte growth factor indicated to\n• Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. •Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT).\n• Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia",
    "hcpcs_code": "Q5110",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Cancer/AML, MDS, ALL-oncologist or a hematologist. Cancer patients receiving BMT and PBPC-prescribed by or in consultation with an oncologist, hematologist, or a physician who specializes in transplantation. Radiation-expertise in acute radiation. SCN-hematologist. HIV/AIDS neutropenia-infectious disease (ID) physician (MD), hematologist, or MD specializing in HIV/AIDS",
    "other_criteria": "Cancer patients receiving chemotherapy, approve if the patient meets one of the\nfollowing conditions: 1)patient is receiving myelosuppressive anti-cancer\nmedications that are associated with a high risk of febrile neutropenia (the risk is\nat least 20% based on the chemotherapy regimen), 2)patient is receiving\nmyelosuppressive anti-cancer medications that are associated with a risk of\nfebrile neutropenia but the risk is less than 20% based on the chemotherapy\nregimen and the patient has one or more risk factors for febrile neutropenia (eg,\naged greater than or equal to 65 years, prior chemotherapy or radiation therapy,\npersistent neutropenia, bone marrow involvement by tumor, recent surgery\nand/or open wounds, liver and/or renal dysfunction, poor performance status, or\nHIV infection), 3)patient has had a neutropenic complication from prior\nchemotherapy and did not receive prophylaxis with a colony stimulating factor\n(eg, Leukine, filgrastim products, pegfilgrastim products) and a reduced dose or\nfrequency of chemotherapy may compromise treatment, or 4)patient has\nreceived chemotherapy has febrile neutropenia and has at least one risk factor\n(eg, sepsis syndrome, aged greater than 65 years, severe neutropenia [absolute\nneutrophil count less than 100 cells/mm3], neutropenia expected to be greater\nthan 10 days in duration, invasive fungal infection).",
    "insurer": "Centene"
  },
  {
    "brand_name": "Nivestym/Nivestim",
    "inn": "filgrastim",
    "therapy_area": "Blood disorders",
    "indication": "Neutropenia",
    "indicated_population": "Neutropenia ( induction or consolidation CT, patients with AML)",
    "label": "NIVESTYM is a leukocyte growth factor indicated to\n• Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. •Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT).\n• Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia",
    "hcpcs_code": "Q5110",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Cancer/AML, MDS, ALL-oncologist or a hematologist. Cancer patients receiving BMT and PBPC-prescribed by or in consultation with an oncologist, hematologist, or a physician who specializes in transplantation. Radiation-expertise in acute radiation. SCN-hematologist. HIV/AIDS neutropenia-infectious disease (ID) physician (MD), hematologist, or MD specializing in HIV/AIDS",
    "other_criteria": "Cancer patients receiving chemotherapy, approve if the patient meets one of the\nfollowing conditions: 1)patient is receiving myelosuppressive anti-cancer\nmedications that are associated with a high risk of febrile neutropenia (the risk is\nat least 20% based on the chemotherapy regimen), 2)patient is receiving\nmyelosuppressive anti-cancer medications that are associated with a risk of\nfebrile neutropenia but the risk is less than 20% based on the chemotherapy\nregimen and the patient has one or more risk factors for febrile neutropenia (eg,\naged greater than or equal to 65 years, prior chemotherapy or radiation therapy,\npersistent neutropenia, bone marrow involvement by tumor, recent surgery\nand/or open wounds, liver and/or renal dysfunction, poor performance status, or\nHIV infection), 3)patient has had a neutropenic complication from prior\nchemotherapy and did not receive prophylaxis with a colony stimulating factor\n(eg, Leukine, filgrastim products, pegfilgrastim products) and a reduced dose or\nfrequency of chemotherapy may compromise treatment, or 4)patient has\nreceived chemotherapy has febrile neutropenia and has at least one risk factor\n(eg, sepsis syndrome, aged greater than 65 years, severe neutropenia [absolute\nneutrophil count less than 100 cells/mm3], neutropenia expected to be greater\nthan 10 days in duration, invasive fungal infection).",
    "insurer": "Centene"
  },
  {
    "brand_name": "Nivestym/Nivestim",
    "inn": "filgrastim",
    "therapy_area": "Blood disorders",
    "indication": "Neutropenia",
    "indicated_population": "Neutropenia (nonmyeloid malignancies, myeloablative CT followed by BMT)",
    "label": "NIVESTYM is a leukocyte growth factor indicated to\n• Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. •Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT).\n• Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia",
    "hcpcs_code": "Q5110",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Cancer/AML, MDS, ALL-oncologist or a hematologist. Cancer patients receiving BMT and PBPC-prescribed by or in consultation with an oncologist, hematologist, or a physician who specializes in transplantation. Radiation-expertise in acute radiation. SCN-hematologist. HIV/AIDS neutropenia-infectious disease (ID) physician (MD), hematologist, or MD specializing in HIV/AIDS",
    "other_criteria": "Cancer patients receiving chemotherapy, approve if the patient meets one of the\nfollowing conditions: 1)patient is receiving myelosuppressive anti-cancer\nmedications that are associated with a high risk of febrile neutropenia (the risk is\nat least 20% based on the chemotherapy regimen), 2)patient is receiving\nmyelosuppressive anti-cancer medications that are associated with a risk of\nfebrile neutropenia but the risk is less than 20% based on the chemotherapy\nregimen and the patient has one or more risk factors for febrile neutropenia (eg,\naged greater than or equal to 65 years, prior chemotherapy or radiation therapy,\npersistent neutropenia, bone marrow involvement by tumor, recent surgery\nand/or open wounds, liver and/or renal dysfunction, poor performance status, or\nHIV infection), 3)patient has had a neutropenic complication from prior\nchemotherapy and did not receive prophylaxis with a colony stimulating factor\n(eg, Leukine, filgrastim products, pegfilgrastim products) and a reduced dose or\nfrequency of chemotherapy may compromise treatment, or 4)patient has\nreceived chemotherapy has febrile neutropenia and has at least one risk factor\n(eg, sepsis syndrome, aged greater than 65 years, severe neutropenia [absolute\nneutrophil count less than 100 cells/mm3], neutropenia expected to be greater\nthan 10 days in duration, invasive fungal infection).",
    "insurer": "Centene"
  },
  {
    "brand_name": "Nivestym/Nivestim",
    "inn": "filgrastim",
    "therapy_area": "Blood disorders",
    "indication": "Neutropenia",
    "indicated_population": "Neutropenia (severe, congenital‚ cyclic or idiopathic, symptomatic)",
    "label": "NIVESTYM is a leukocyte growth factor indicated to\n• Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. •Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML). • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT).\n• Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia",
    "hcpcs_code": "Q5110",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Cancer/AML, MDS, ALL-oncologist or a hematologist. Cancer patients receiving BMT and PBPC-prescribed by or in consultation with an oncologist, hematologist, or a physician who specializes in transplantation. Radiation-expertise in acute radiation. SCN-hematologist. HIV/AIDS neutropenia-infectious disease (ID) physician (MD), hematologist, or MD specializing in HIV/AIDS",
    "other_criteria": "Cancer patients receiving chemotherapy, approve if the patient meets one of the\nfollowing conditions: 1)patient is receiving myelosuppressive anti-cancer\nmedications that are associated with a high risk of febrile neutropenia (the risk is\nat least 20% based on the chemotherapy regimen), 2)patient is receiving\nmyelosuppressive anti-cancer medications that are associated with a risk of\nfebrile neutropenia but the risk is less than 20% based on the chemotherapy\nregimen and the patient has one or more risk factors for febrile neutropenia (eg,\naged greater than or equal to 65 years, prior chemotherapy or radiation therapy,\npersistent neutropenia, bone marrow involvement by tumor, recent surgery\nand/or open wounds, liver and/or renal dysfunction, poor performance status, or\nHIV infection), 3)patient has had a neutropenic complication from prior\nchemotherapy and did not receive prophylaxis with a colony stimulating factor\n(eg, Leukine, filgrastim products, pegfilgrastim products) and a reduced dose or\nfrequency of chemotherapy may compromise treatment, or 4)patient has\nreceived chemotherapy has febrile neutropenia and has at least one risk factor\n(eg, sepsis syndrome, aged greater than 65 years, severe neutropenia [absolute\nneutrophil count less than 100 cells/mm3], neutropenia expected to be greater\nthan 10 days in duration, invasive fungal infection).",
    "insurer": "Centene"
  },
  {
    "brand_name": "Nivestym/Nivestim",
    "inn": "filgrastim",
    "therapy_area": "Transplantation",
    "indication": "Cell transplantation",
    "indicated_population": "Hematopoietic progenitor cell transplantation (for collection by leukapheresis)",
    "label": "NIVESTYM is a leukocyte growth factor indicated to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.",
    "hcpcs_code": "Q5110",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Cancer/AML, MDS, ALL-oncologist or a hematologist. Cancer patients receiving BMT and PBPC-prescribed by or in consultation with an oncologist, hematologist, or a physician who specializes in transplantation. Radiation-expertise in acute radiation. SCN-hematologist. HIV/AIDS neutropenia-infectious disease (ID) physician (MD), hematologist, or MD specializing in HIV/AIDS",
    "other_criteria": "Cancer patients receiving chemotherapy, approve if the patient meets one of the\nfollowing conditions: 1)patient is receiving myelosuppressive anti-cancer\nmedications that are associated with a high risk of febrile neutropenia (the risk is\nat least 20% based on the chemotherapy regimen), 2)patient is receiving\nmyelosuppressive anti-cancer medications that are associated with a risk of\nfebrile neutropenia but the risk is less than 20% based on the chemotherapy\nregimen and the patient has one or more risk factors for febrile neutropenia (eg,\naged greater than or equal to 65 years, prior chemotherapy or radiation therapy,\npersistent neutropenia, bone marrow involvement by tumor, recent surgery\nand/or open wounds, liver and/or renal dysfunction, poor performance status, or\nHIV infection), 3)patient has had a neutropenic complication from prior\nchemotherapy and did not receive prophylaxis with a colony stimulating factor\n(eg, Leukine, filgrastim products, pegfilgrastim products) and a reduced dose or\nfrequency of chemotherapy may compromise treatment, or 4)patient has\nreceived chemotherapy has febrile neutropenia and has at least one risk factor\n(eg, sepsis syndrome, aged greater than 65 years, severe neutropenia [absolute\nneutrophil count less than 100 cells/mm3], neutropenia expected to be greater\nthan 10 days in duration, invasive fungal infection).",
    "insurer": "Centene"
  },
  {
    "brand_name": "Nyvepria",
    "inn": "pegfilgrastim",
    "therapy_area": "Blood disorders",
    "indication": "Neutropenia",
    "indicated_population": "Neutropenia (in patients with non-myeloid malignancies)",
    "label": "NYVEPRIA is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.",
    "hcpcs_code": "Q5122",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Cancer patients receiving chemotherapy-prescribed by or in consultation with an oncologist or hematologist. PBPC-prescribed by or in consultation with an oncologist, hematologist, or physician that specializes in transplantation.",
    "other_criteria": "Cancer patients receiving chemotherapy, approve if the patient meets one of the\nfollowing: 1) is receiving myelosuppressive anti-cancer medications that are\nassociated with a high risk of febrile neutropenia (the risk is at least 20% based\non the chemotherapy regimen), 2) patient is receiving myelosuppressive anticancer medications that are associated with a risk of febrile neutropenia but the\nrisk is less than 20% based on the chemotherapy regimen and the patient has\none or more risk factors for febrile neutropenia according to the prescribing\nphysician (eg, aged greater than or equal to 65 years, prior chemotherapy or\nradiation therapy, persistent neutropenia, bone marrow involvement by tumor,\nrecent surgery and/or open wounds, liver and/or renal dysfunction, poor\nperformance status or HIV infection, or 3) patient has had a neutropenic\ncomplication from prior chemotherapy and did not receive prophylaxis with a\ncolony stimulating factor and a reduced dose or frequency of chemotherapy may\ncompromise treatment.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ocrevus",
    "inn": "ocrelizumab",
    "therapy_area": "Nervous system disorders",
    "indication": "Multiple sclerosis",
    "indicated_population": "MS (relapsing-remitting, adults)",
    "label": "Ocrevus is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis",
    "hcpcs_code": "J2350",
    "exclusion_criteria": "Concurrent use with other Disease-Modifying Agents used for MS",
    "age_restrictions": "18 years of age and older (initial/continuation)",
    "prescriber_restrictions": "Prescribed by, or in consultation with, a physician who specializes in the treatment of MS and/or a neurologist (initial/continuation)",
    "other_criteria": "Relapsing forms of MS-Patients new to therapy-approve if the patient had a trial\nwith generic dimethyl fumarate prior to approval of Ocrevus. (Note: Prior\ntreatment with Tecfidera, Bafiertam or Vumerity also counts. Also, a patient who\nhas previously tried a glatiramer product (Copaxone, Glatopa, generic) or\nLemtrada, Tysabri or Kesimpta can bypass the requirement of a trial of generic\ndimethyl fumarate). Continuation-approve if the patient has responded to\ntherapy. Primary progressive MS-approve.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ocrevus",
    "inn": "ocrelizumab",
    "therapy_area": "Nervous system disorders",
    "indication": "Multiple sclerosis",
    "indicated_population": "MS (secondary progressive, active, adults)",
    "label": "Ocrevus is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis",
    "hcpcs_code": "J2350",
    "exclusion_criteria": "Concurrent use with other Disease-Modifying Agents used for MS",
    "age_restrictions": "18 years of age and older (initial/continuation)",
    "prescriber_restrictions": "Prescribed by, or in consultation with, a physician who specializes in the treatment of MS and/or a neurologist (initial/continuation)",
    "other_criteria": "Relapsing forms of MS-Patients new to therapy-approve if the patient had a trial\nwith generic dimethyl fumarate prior to approval of Ocrevus. (Note: Prior\ntreatment with Tecfidera, Bafiertam or Vumerity also counts. Also, a patient who\nhas previously tried a glatiramer product (Copaxone, Glatopa, generic) or\nLemtrada, Tysabri or Kesimpta can bypass the requirement of a trial of generic\ndimethyl fumarate). Continuation-approve if the patient has responded to\ntherapy. Primary progressive MS-approve.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ocrevus",
    "inn": "ocrelizumab",
    "therapy_area": "Nervous system disorders",
    "indication": "Multiple sclerosis",
    "indicated_population": "MS (clinically isolated syndrome, adults)",
    "label": "Ocrevus is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis",
    "hcpcs_code": "J2350",
    "exclusion_criteria": "Concurrent use with other Disease-Modifying Agents used for MS",
    "age_restrictions": "18 years of age and older (initial/continuation)",
    "prescriber_restrictions": "Prescribed by, or in consultation with, a physician who specializes in the treatment of MS and/or a neurologist (initial/continuation)",
    "other_criteria": "Relapsing forms of MS-Patients new to therapy-approve if the patient had a trial\nwith generic dimethyl fumarate prior to approval of Ocrevus. (Note: Prior\ntreatment with Tecfidera, Bafiertam or Vumerity also counts. Also, a patient who\nhas previously tried a glatiramer product (Copaxone, Glatopa, generic) or\nLemtrada, Tysabri or Kesimpta can bypass the requirement of a trial of generic\ndimethyl fumarate). Continuation-approve if the patient has responded to\ntherapy. Primary progressive MS-approve.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ocrevus",
    "inn": "ocrelizumab",
    "therapy_area": "Nervous system disorders",
    "indication": "Multiple sclerosis",
    "indicated_population": "MS (primary progressive, adults)",
    "label": "Ocrevus is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis",
    "hcpcs_code": "J2350",
    "exclusion_criteria": "Concurrent use with other Disease-Modifying Agents used for MS",
    "age_restrictions": "18 years of age and older (initial/continuation)",
    "prescriber_restrictions": "Prescribed by, or in consultation with, a physician who specializes in the treatment of MS and/or a neurologist (initial/continuation)",
    "other_criteria": "Relapsing forms of MS-Patients new to therapy-approve if the patient had a trial\nwith generic dimethyl fumarate prior to approval of Ocrevus. (Note: Prior\ntreatment with Tecfidera, Bafiertam or Vumerity also counts. Also, a patient who\nhas previously tried a glatiramer product (Copaxone, Glatopa, generic) or\nLemtrada, Tysabri or Kesimpta can bypass the requirement of a trial of generic\ndimethyl fumarate). Continuation-approve if the patient has responded to\ntherapy. Primary progressive MS-approve.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ruxience",
    "inn": "rituximab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Rheumatoid arthritis",
    "indicated_population": "RA (active, severe, TNFα antagonist IR or IT)",
    "label": "RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of:\nRheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies.",
    "hcpcs_code": "Q5119",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Not available",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ruxience",
    "inn": "rituximab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Wegener’s and microscopic polyangiitis",
    "indicated_population": "GPA (severe, active)",
    "label": "RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of:\nGranulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) in adult patients in combination with glucocorticoids",
    "hcpcs_code": "Q5119",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Not available",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ruxience",
    "inn": "rituximab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Wegener’s and microscopic polyangiitis",
    "indicated_population": "MPA (severe, active)",
    "label": "RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of:\nGranulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) in adult patients in combination with glucocorticoids",
    "hcpcs_code": "Q5119",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Not available",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ruxience",
    "inn": "rituximab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Pemphigus vulgaris",
    "indicated_population": "Pemphigus vulgaris (moderate to severe)",
    "label": "Ruxience is a CD20-directed cytolytic antibody indicated for the treatment of moderate to severe pemphigus vulgaris (PV) in adult patients.",
    "hcpcs_code": "Q5119",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Not available",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ruxience",
    "inn": "rituximab",
    "therapy_area": "Oncology",
    "indication": "Chronic lymphocytic leukaemia",
    "indicated_population": "CLL (naïve)",
    "label": "RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Chronic Lymphocytic Leukemia (CLL) ○ Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).",
    "hcpcs_code": "Q5119",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Not available",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ruxience",
    "inn": "rituximab",
    "therapy_area": "Oncology",
    "indication": "Chronic lymphocytic leukaemia",
    "indicated_population": "CLL (relapsed)",
    "label": "RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Chronic Lymphocytic Leukemia (CLL) ○ Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC).",
    "hcpcs_code": "Q5119",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Not available",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ruxience",
    "inn": "rituximab",
    "therapy_area": "Oncology",
    "indication": "Diffuse large B-cell lymphoma",
    "indicated_population": "DLBCL (CD20+, in combi with CHOP)",
    "label": "RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens.",
    "hcpcs_code": "Q5119",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Not available",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ruxience",
    "inn": "rituximab",
    "therapy_area": "Oncology",
    "indication": "Follicular lymphoma",
    "indicated_population": "FL (Stage III-IV, CT IR or IT)",
    "label": "RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of:\n• Adult patients with Non-Hodgkin’s Lymphoma (NHL).\n○ Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent.\n○ Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.\n○ Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.",
    "hcpcs_code": "Q5119",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Not available",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ruxience",
    "inn": "rituximab",
    "therapy_area": "Oncology",
    "indication": "Follicular lymphoma",
    "indicated_population": "FL (relapsed, responding to induction therapy with CT with or without MabThera)",
    "label": "RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of:\n• Adult patients with Non-Hodgkin’s Lymphoma (NHL).\n○ Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent.\n○ Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.\n○ Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.",
    "hcpcs_code": "Q5119",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Not available",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Ruxience",
    "inn": "rituximab",
    "therapy_area": "Oncology",
    "indication": "Follicular lymphoma",
    "indicated_population": "FL (Stage III-IV, naive)",
    "label": "RUXIENCE (rituximab-pvvr) is a CD20-directed cytolytic antibody indicated for the treatment of:\n• Adult patients with Non-Hodgkin’s Lymphoma (NHL).\n○ Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent.\n○ Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy.\n○ Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy.",
    "hcpcs_code": "Q5119",
    "exclusion_criteria": "Not available",
    "age_restrictions": "Not available",
    "prescriber_restrictions": "Not available",
    "other_criteria": "Part B versus Part D determination will be made at time of prior authorization\nreview per CMS guidance.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Stelara",
    "inn": "ustekinumab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Pediatric plaque psoriasis",
    "indicated_population": "PsO (moderate to severe, in pediatrics of 6 years and older, systemic therapy IR)",
    "label": "Stelara is a human interleukin-12 and -23 antagonist indicated for the treatment of pediatric patients 6 years and older with moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy.",
    "hcpcs_code": "J3357",
    "exclusion_criteria": "Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD",
    "age_restrictions": "PP-6 years and older (initial therapy).",
    "prescriber_restrictions": "Plaque psoriasis.Prescribed by or in consultation with a dermatologist (initial therapy).  PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy). CD/UC-prescribed by or in consultation with a gastroenterologist (initial therapy).",
    "other_criteria": "",
    "insurer": "Centene"
  },
  {
    "brand_name": "Stelara",
    "inn": "ustekinumab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Pediatric plaque psoriasis",
    "indicated_population": "PsO (moderate to severe, in pediatrics of 12 years and older, systemic therapy IR)",
    "label": "Stelara is a human interleukin-12 and -23 antagonist indicated for the treatment of pediatric patients 6 years and older with moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy.",
    "hcpcs_code": "J3357",
    "exclusion_criteria": "Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD",
    "age_restrictions": "PP-6 years and older (initial therapy).",
    "prescriber_restrictions": "Plaque psoriasis.Prescribed by or in consultation with a dermatologist (initial therapy).  PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy). CD/UC-prescribed by or in consultation with a gastroenterologist (initial therapy).",
    "other_criteria": "",
    "insurer": "Centene"
  },
  {
    "brand_name": "Stelara",
    "inn": "ustekinumab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Psoriatic arthritis",
    "indicated_population": "PsA (active)",
    "label": "Stelara is a human interleukin-12 and -23 antagonist indicated for the treatment of pediatric patients 6 years and older with active psoriatic arthritis (PsA).",
    "hcpcs_code": "J3357",
    "exclusion_criteria": "Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD",
    "age_restrictions": "PP-6 years and older (initial therapy).",
    "prescriber_restrictions": "Plaque psoriasis.Prescribed by or in consultation with a dermatologist (initial therapy).  PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy). CD/UC-prescribed by or in consultation with a gastroenterologist (initial therapy).",
    "other_criteria": "",
    "insurer": "Centene"
  },
  {
    "brand_name": "Stelara",
    "inn": "ustekinumab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Psoriatic arthritis",
    "indicated_population": "PsA (active, in pediatrics of 6 years and older)",
    "label": "Stelara is a human interleukin-12 and -23 antagonist indicated for the treatment of pediatric patients 6 years and older with active psoriatic arthritis (PsA).",
    "hcpcs_code": "J3357",
    "exclusion_criteria": "Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD",
    "age_restrictions": "PP-6 years and older (initial therapy).",
    "prescriber_restrictions": "Plaque psoriasis.Prescribed by or in consultation with a dermatologist (initial therapy).  PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy). CD/UC-prescribed by or in consultation with a gastroenterologist (initial therapy).",
    "other_criteria": "",
    "insurer": "Centene"
  },
  {
    "brand_name": "Stelara",
    "inn": "ustekinumab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Ulcerative colitis",
    "indicated_population": "UC (active, moderate to severe)",
    "label": "Stelara® is a human interleukin-12 and -23 antagonist indicated for the treatment of: ? moderately to severely active ulcerative colitis.",
    "hcpcs_code": "J3357",
    "exclusion_criteria": "Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD",
    "age_restrictions": "PP-6 years and older (initial therapy).",
    "prescriber_restrictions": "Plaque psoriasis.Prescribed by or in consultation with a dermatologist (initial therapy).  PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy). CD/UC-prescribed by or in consultation with a gastroenterologist (initial therapy).",
    "other_criteria": "ULCERATIVE COLITIS (UC) [A and B]: A) receiving/received single IV loading dose within 2 months of initiating therapy with Ustekinumab SC and B) meets one of the following (a or b): a) tried one systemic agent or b) has pouchitis and tried an antibiotic, probiotic, CS enema or mesalamine enema.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Stelara",
    "inn": "ustekinumab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Psoriasis",
    "indicated_population": "PsO (moderate to severe, systemic therapy IR)",
    "label": "Stelara is a human interleukin-12 and -23 antagonist indicated for the treatment of Adult patients with moderate to severe plaque psoriasis (Ps) who are candidates for phototherapy or systemic therapy.",
    "hcpcs_code": "J3357",
    "exclusion_criteria": "Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD",
    "age_restrictions": "PP-6 years and older (initial therapy).",
    "prescriber_restrictions": "Plaque psoriasis.Prescribed by or in consultation with a dermatologist (initial therapy).  PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy). CD/UC-prescribed by or in consultation with a gastroenterologist (initial therapy).",
    "other_criteria": "",
    "insurer": "Centene"
  },
  {
    "brand_name": "Stelara",
    "inn": "ustekinumab",
    "therapy_area": "Gastroenterology",
    "indication": "Crohn’s disease",
    "indicated_population": "CD (active, moderate to severe, conventional therapy or TNFα antagonist IR or IT)",
    "label": "Stelara is a human interleukin-12 and -23 antagonist indicated for the treatment of Adult patients with moderately to severely active Crohn’s disease (CD) who have failed or were intolerant to treatment with immunomodulators or corticosteroids, but never failed a tumor necrosis factor (TNF) blocker or failed or were intolerant to treatment with one or more TNF blockers.",
    "hcpcs_code": "J3357",
    "exclusion_criteria": "Ustekinumab should not be given in combination with a Biologic DMARD or Targeted Synthetic DMARD",
    "age_restrictions": "PP-6 years and older (initial therapy).",
    "prescriber_restrictions": "Plaque psoriasis.Prescribed by or in consultation with a dermatologist (initial therapy).  PsA-prescribed by or in consultation with a rheumatologist or dermatologist (initial therapy). CD/UC-prescribed by or in consultation with a gastroenterologist (initial therapy).",
    "other_criteria": "CROHN'S DISEASE (CD) [A and B]: A) receiving/received single IV loading dose within 2 months of initiating therapy with Ustekinumab SC, and B) (a, b, c or d): a) tried or is currently taking corticosteroids (CS), or CS are contraindicated, b) tried one conventional systemic therapy, c) has enterocutaneous (perianal or abdominal) or rectovaginal fistulas, or d) had ileocolonic resection to reduce the chance of\nCD recurrence.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Tremfya",
    "inn": "guselkumab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Psoriasis",
    "indicated_population": "PsO (moderate to severe, systemic therapy IR)",
    "label": "Tremfya is an interleukin-23 blocker indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy",
    "hcpcs_code": "J1628",
    "exclusion_criteria": "Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)",
    "age_restrictions": "PP/UC/CD- 18 years of age and older (initial therapy)",
    "prescriber_restrictions": "PP-Prescribed by or in consultation with a dermatologist (initial therapy only). PsA-prescribed by or in consultation with a dermatologist or rheumatologist (initial therapy). UC/CD-prescribed by or in consultation with a gastroenterologist (initial therapy).",
    "other_criteria": "",
    "insurer": "Centene"
  },
  {
    "brand_name": "Tremfya",
    "inn": "guselkumab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Psoriatic arthritis",
    "indicated_population": "PsA (active)",
    "label": "Tremfya is an interleukin-23 blocker indicated for the treatment of adult patients with active psoriatic arthritis.",
    "hcpcs_code": "J1628",
    "exclusion_criteria": "Concurrent Use with other Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs (DMARDs)",
    "age_restrictions": "PP/UC/CD- 18 years of age and older (initial therapy)",
    "prescriber_restrictions": "PP-Prescribed by or in consultation with a dermatologist (initial therapy only). PsA-prescribed by or in consultation with a dermatologist or rheumatologist (initial therapy). UC/CD-prescribed by or in consultation with a gastroenterologist (initial therapy).",
    "other_criteria": "",
    "insurer": "Centene"
  },
  {
    "brand_name": "Xolair",
    "inn": "omalizumab",
    "therapy_area": "Autoimmune disorders",
    "indication": "Urticaria",
    "indicated_population": "Urticaria (chronic, in patients with age of 12 years and older, H1 antihistamine IR)",
    "label": "Xolair is an anti-IgE antibody indicated for chronic idiopathic urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment",
    "hcpcs_code": "J2357",
    "exclusion_criteria": "Concurrent use with another monoclonal antibody therapy.",
    "age_restrictions": "Moderate to severe persistent asthma-6 years and older. CIU-12 years and older. Polyps-18 years and older. Food Allergy-1 yr and older",
    "prescriber_restrictions": "Moderate to severe persistent asthma if prescribed by, or in consultation with an allergist, immunologist, or pulmonologist. CIU if prescribed by or in consultation with an allergist, immunologist, or dermatologist. Polyps-prescribed by or in consult with an allergist, immunologist, or otolaryngologist. Food allergy- allergist or immunologist",
    "other_criteria": "CHRONIC\nIDIOPATHIC URTICARIA (CIU): urticaria more than 6 weeks prior to treatment with\nXolair with symptoms pesent more than 3 days per week despite daily nonsedating H1-antihistamine therapy. IgE-MEDIATED FOOD ALLERGY (all of A, B, C\nand D): A) baseline IgE greater than or equal to 30 IU/mL, B) positive skin prick\ntest or positive in vitro test for IgE to one or more foods, C) history of allergic\nreaction that met all of the following (a, b, and c): a) signs and symptoms of a\nsignificant systemic allergic reaction, b) reaction occurred within a short period\nof time following a known ingestion of the food, and c) prescriber deemed this\nreaction significant enough to require a prescription for an epinephrine autoinjector, and D) patient has been prescribed an epinephrine auto-injector.\nCONTINUATION THERAPY: ASTHMA: patient responded to therapy and continues\nto receive an ICS.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Xolair",
    "inn": "omalizumab",
    "therapy_area": "Miscellaneous",
    "indication": "Allergic reactions",
    "indicated_population": "Allergic reactions (IgE-mediated food allergy, 1 year and older)",
    "label": "Xolair is an anti-IgE antibody indicated for IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance.",
    "hcpcs_code": "J2357",
    "exclusion_criteria": "Concurrent use with another monoclonal antibody therapy.",
    "age_restrictions": "Moderate to severe persistent asthma-6 years and older. CIU-12 years and older. Polyps-18 years and older. Food Allergy-1 yr and older",
    "prescriber_restrictions": "Moderate to severe persistent asthma if prescribed by, or in consultation with an allergist, immunologist, or pulmonologist. CIU if prescribed by or in consultation with an allergist, immunologist, or dermatologist. Polyps-prescribed by or in consult with an allergist, immunologist, or otolaryngologist. Food allergy- allergist or immunologist",
    "other_criteria": "",
    "insurer": "Centene"
  },
  {
    "brand_name": "Xolair",
    "inn": "omalizumab",
    "therapy_area": "Respiratory disease",
    "indication": "Asthma",
    "indicated_population": "Asthma (allergic, moderate to severe, inhaled corticosteroids IR, 12 years and older)",
    "label": "Xolair is an anti-IgE antibody indicated for moderate to severe persistent asthma in patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids",
    "hcpcs_code": "J2357",
    "exclusion_criteria": "Concurrent use with another monoclonal antibody therapy.",
    "age_restrictions": "Moderate to severe persistent asthma-6 years and older. CIU-12 years and older. Polyps-18 years and older. Food Allergy-1 yr and older",
    "prescriber_restrictions": "Moderate to severe persistent asthma if prescribed by, or in consultation with an allergist, immunologist, or pulmonologist. CIU if prescribed by or in consultation with an allergist, immunologist, or dermatologist. Polyps-prescribed by or in consult with an allergist, immunologist, or otolaryngologist. Food allergy- allergist or immunologist",
    "other_criteria": "MODERATE TO SEVERE PERSISTENT ASTHMA (A, B, C and D): A) baseline IgE greater than or equal to 30 IU/mL, and B) baseline positive skin test or in vitro test for 1 or more perennial or seasonal aeroallergens C) received at least 3 months of combination therapy with an inhaled corticosteroid (ICS) and additional asthma controller/maintenance medication (e.g., LABA, LAMA, leukotriene receptor antagonist, monoclonal antibody) [see Exception 1 below] and D) asthma is uncontrolled or was uncontrolled prior to receiving Xolair or another monoclonal antibody and meets one of the following (a, b, c, d, or e): a) experienced two or more asthma exacerbations requiring systemic CSs in the past year, b) experienced one or more asthma exacerbation requiring hospitalization/urgent care visit/emergency department visit in the past year, c) forced expiratory volume in 1 second (FEV1) less than 80% predicted, d) FEV1/forced vital capacity (FVC) less than 0.80, or e) asthma worsens upon tapering of oral CS.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Xolair",
    "inn": "omalizumab",
    "therapy_area": "Respiratory disease",
    "indication": "Asthma",
    "indicated_population": "Asthma (severe, allergic, inhaled corticosteroids IR, 6years and older)",
    "label": "Xolair is an anti-IgE antibody indicated for moderate to severe persistent asthma in patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids",
    "hcpcs_code": "J2357",
    "exclusion_criteria": "Concurrent use with another monoclonal antibody therapy.",
    "age_restrictions": "Moderate to severe persistent asthma-6 years and older. CIU-12 years and older. Polyps-18 years and older. Food Allergy-1 yr and older",
    "prescriber_restrictions": "Moderate to severe persistent asthma if prescribed by, or in consultation with an allergist, immunologist, or pulmonologist. CIU if prescribed by or in consultation with an allergist, immunologist, or dermatologist. Polyps-prescribed by or in consult with an allergist, immunologist, or otolaryngologist. Food allergy- allergist or immunologist",
    "other_criteria": "MODERATE TO SEVERE PERSISTENT ASTHMA (A, B, C and D): A) baseline IgE greater than or equal to 30 IU/mL, and B) baseline positive skin test or in vitro test for 1 or more perennial or seasonal aeroallergens C) received at least 3 months of combination therapy with an inhaled corticosteroid (ICS) and additional asthma controller/maintenance medication (e.g., LABA, LAMA, leukotriene receptor antagonist, monoclonal antibody) [see Exception 1 below] and D) asthma is uncontrolled or was uncontrolled prior to receiving Xolair or another monoclonal antibody and meets one of the following (a, b, c, d, or e): a) experienced two or more asthma exacerbations requiring systemic CSs in the past year, b) experienced one or more asthma exacerbation requiring hospitalization/urgent care visit/emergency department visit in the past year, c) forced expiratory volume in 1 second (FEV1) less than 80% predicted, d) FEV1/forced vital capacity (FVC) less than 0.80, or e) asthma worsens upon tapering of oral CS.",
    "insurer": "Centene"
  },
  {
    "brand_name": "Xolair",
    "inn": "omalizumab",
    "therapy_area": "Respiratory disease",
    "indication": "Chronic rhinosinusitis with nasal polyps",
    "indicated_population": "CRSwNP (severe, intranasal corticosteroids IR)",
    "label": "Xolair is an anti-IgE antibody indicated for chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment.",
    "hcpcs_code": "J2357",
    "exclusion_criteria": "Concurrent use with another monoclonal antibody therapy.",
    "age_restrictions": "Moderate to severe persistent asthma-6 years and older. CIU-12 years and older. Polyps-18 years and older. Food Allergy-1 yr and older",
    "prescriber_restrictions": "Moderate to severe persistent asthma if prescribed by, or in consultation with an allergist, immunologist, or pulmonologist. CIU if prescribed by or in consultation with an allergist, immunologist, or dermatologist. Polyps-prescribed by or in consult with an allergist, immunologist, or otolaryngologist. Food allergy- allergist or immunologist",
    "other_criteria": "CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRwNP) [all\nof A, B, C, D, and E]: A) diagnosis by direct exam, endoscopy, or sinus CT scan,\nB) baseline (prior to Xolair or another monoclonal antibody that may lower IgE)\nIgE at least 30 IU/ml, C) at least two of the following symptoms for 6 months:\nnasal congestion, obstruction, discharge, reduction/loss of smell, D) tried\nintranasal CS and will continue in combination with Xolair, and E) one of the\nfollowing (a, b, or c): a) had systemic CS at least 5 days in past 2 years, b)\ncontraindication to systemic CS, or c) had nasal polyp surgery.",
    "insurer": "Centene"
  }
]